Nebenwirkungen · Vimpat
Treatment initiation pack (in adolescents and children weighing 50 kg or more and adults only) Vimpat 50 mg film-coated tablets Vimpat 100 mg film-coated tablets Vimpat 150 mg film-coated tablets Vimpat 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 29
HOS-119487 · Präparat HOS-094947
Based on the analysis of data from a non-inferiority monotherapy clinical study comparing lacosamide to carbamazepine controlled release (CR), the most frequently reported adverse reactions (≥ 10 %) for lacosamide were headache and dizziness. The discontinuation rate due to adverse reactions was 10.6 % for patients treated with lacosamide and 15.6 % for patients treated with carbamazepine CR.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:46:00Z · SHA-256 5f9684302e7c8a579e94d70f499a6979b21c5d712f752fe49c5607a3581bef64 · Passage a0cca5f1b284e48b1581deefd15df204d2908d31e9929a05253a800de0839c0c · Zeichen 967–1362 im Abschnitt